DIAGNOSTIC METHOD OF CARDIOVASCULAR DISEASE

• US 20150198582A1
• Filed: 02/20/2014
• Published: 07/16/2015
• Est. Priority Date: 01/14/2014
• Status: Active Grant

• Current Assignee: Korea Advanced Institute of Science and Technology
• Original Assignee: Korea Advanced Institute of Science and Technology
• Inventors: JUNG, Byung Hwa, CHOI, Jong Min
• Granted Patent: US 9,354,222 B2
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: G01N 2800/324 Coronary artery diseases, e.g. angina pectoris, myocardial infarction
• CPC Class Codes: G01N 30/72 Mass spectrometers mass spectrometers per se H01J49/00
• CPC Class Codes: G01N 33/492 Determining multiple analytes
• CPC Class Codes: G01N 33/92 involving lipids, e.g. cholesterol , lipoproteins, or their receptors steroid hormones G01N33/743
• CPC Class Codes: Y10T 436/24 Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Abstract

Biological metabolites LysoPC (18:0), LysoPC (20:3), fatty acid (16:1), fatty acid (18:0), fatty acid (18:1), fatty acid (18:2) and fatty acid (22:6) according to the present disclosure allow for simple and accurate diagnosis of a cardiovascular disease since their level in the blood of a subject increases or decreases if the subject has a cardiovascular disease such as myocardial infarction or angina. In addition, whereas the existing biomarkers can diagnose only whether myocardial infarction occurs or not, the biological metabolites according to the present disclosure can diagnose not only myocardial infarction but also unstable angina occurring prior to the onset of myocardial infarction stage by stage.

Claims

1. A method for diagnosing a cardiovascular disease, comprising:

measuring the level of one or more biological metabolite selected from lysophosphatidylcholine (LysoPC) (18;

0), LysoPC (20;

3), fatty acid (16;

1), fatty acid (18;

0), fatty acid (18;

1), fatty acid (18;

2) and fatty acid (22;

6) in blood taken from a subject; and

comparing the level of the biological metabolite in the blood with the level of the biological metabolite in blood from a normal control group.

2. The method for diagnosing a cardiovascular disease according to claim 1, wherein said comparing the level of the biological metabolite further comprises diagnosing that the subject has a cardiovascular disease if the level of at least one of LysoPC (20:

3), fatty acid (16;

1), fatty acid (18;

1), fatty acid (18;

2) and fatty acid (22;

6) in the blood of the subject is higher as compared to the normal control group.

3. The method for diagnosing a cardiovascular disease according to claim 1, wherein said comparing the level of the biological metabolite further comprises diagnosing that the subject has a cardiovascular disease if the level of at least one of LysoPC (18:

0) and fatty acid (18;

0) in the blood of the subject is lower as compared to the normal control group.

4. The method for diagnosing a cardiovascular disease according to claim 1, wherein the cardiovascular disease comprises at least one of myocardial infarction and unstable angina occurring prior to the onset of the myocardial infarction.

5. A kit for diagnosing a cardiovascular disease, comprising a measuring unit measuring one or more biological metabolite selected from lysophosphatidylcholine (LysoPC) (18:

0), LysoPC (20;

3), fatty acid (16;

1), fatty acid (18;

0), fatty acid (18;

1), fatty acid (18;

2) and fatty acid (22;

6).

6. The kit for diagnosing a cardiovascular disease according to claim 5, wherein the cardiovascular disease comprises at least one of myocardial infarction and unstable angina.

7. The kit for diagnosing a cardiovascular disease according to claim 5, which further comprises an instruction including a method for diagnosing a cardiovascular disease.